Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;37(2):166-72.
doi: 10.15537/smj.2016.2.14263.

Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography

Haitham I Sakr  1 , Hussein S Alamri, Abdulrahman M Almoghairi, Ashraf A Alkhudair, Ali S AlMasood
Affiliations

Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography

Haitham I Sakr et al. Saudi Med J. 2016 Feb.

Abstract

Objectives: To estimate the prevalence of clopidogrel non-response and identify its risk factors among Saudi patients.

Methods: This cross-sectional study was conducted at Prince Sultan Cardiac Center, Riyadh, Kingdom of Saudi Arabia between January and June 2013, to assess the degree of platelet inhibition using the VerifyNow assay (Accumetrics, San Diego, CA, USA) after receiving clopidogrel standard loading dose. Clopidogrel resistance was defined as ≤15% platelet inhibition or greater than 213 P2Y12 reaction units (PRU).

Results: Three hundred and four patients were included in the study. The mean age was 60.3 ± 11.4 years, and 73% were males. Clopidogrel doses were 300 mg (57%), 600 mg (27%), and 75 mg (16%). All patients used aspirin (81 mg in 94%). Approximately 66% (200/304) showed in vitro clopidogrel non-response, 54% had low platelet inhibitions, and 61% had high post-loading PRU. Using multivariate regression analysis that included all significant characteristics; only diabetes (odds ratio [OR]: 2.36, 95% confidence interval [CI]: 1.30-4.27, p=0.005) and higher preloading PRU (OR: 2.39, 95% CI: 1.40-4.11, p=0.002) remained significantly associated with higher clopidogrel non-response while myocardial infarction (OR: 0.34, 95% CI: 0.15-0.81, p=0.014) remained significantly associated with lower clopidogrel non-response. The associations of morbid obesity and diuretics use with higher clopidogrel non-response were slightly attenuated.

Conclusion: Our findings indicate a high rate of clopidogrel in-vitro non-response among Saudi patients undergoing coronary angiography.

PubMed Disclaimer

References

    1. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol. 1997;80:17E–20E. - PubMed
    1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 1994;308:81–106. - PMC - PubMed
    1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med. 2001;345:494–502. - PubMed
    1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). Caprie Steering Committee. Lancet. 1996;348:1329–1339. - PubMed
    1. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: Mechanisms and clinical measurements. Nat Rev Cardiol. 2009;6:273–282. - PubMed

MeSH terms